Effect of large tumor size on cancer-specific mortality in node-negative breast cancer

Mayo Clinic Proceedings

Volumn 87, Issue 12, 2012, Pages 1171-1180

  Yu, Ke Da ^a   Jiang, Yi Zhou ^a   Chen, Sheng ^a   Cao, Zhi Gang ^a   Wu, Jiong ^a   Shen, Zhen Zhou ^a   Shao, Zhi Ming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER MORTALITY; CANCER RISK; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HAZARD RATIO; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; RISK ASSESSMENT; RISK REDUCTION; TUMOR VOLUME;

EID: 84872892962     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.07.023     Document Type: Article

References (14)

1. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16(10):1569-1583.
2. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20(17):3628-3636.
3. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181-187.
4. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Tenyear outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol. 2004;22(9):1630-1637.
5. Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13(1):58-68.
6. Wo JY, Chen K, Neville BA, Lin NU, Punglia RS. Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol. 2011;29(19):2619-2627.
7. Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999;8(12):1117-1121.
8. Chen S, Chen CM, Yu KD, Yang WT, Shao ZM. A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer. J Surg Oncol. 2012;105(6):577-585.
9. Norton L, Massague J. Is cancer a disease of self-seeding? Nat Med. 2006;12(8):875-878.
10. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(13):7737-7742.
11. Altan E, Altundag K. Clinical and pathological characteristics of occult breast cancer and review of the literature. J BUON. 2011;16(3):434-436.
12. Comen EA, Norton L, Massague J. Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy. J Clin Oncol. 2011;29(19):2610-2612.
13. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
14. Doane AS, Danso M, Lal P, et al. An estrogen receptornegative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25(28):3994-4008.